|
Aurobindo Pharma Ltd announced that its wholly owned subsidiary, Eugia Pharma Specialities Ltd has received a warning letter from US FDA for Unit-I, a formulation manufacturing facility in Telangana.
"There is no impact on the existing supplies to the US markets. Unit I of Eugia Pharma Specialities Ltd., is contributing ~2% to company’s overall group revenue," the company stated.
Earlier in May 24, 2026, a Formulation manufacturing facility of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, received Official Action Indicated (OAI) status by the US FDA.
The company remains committed to working closely with the US FDA and continues to enhance its compliance on an ongoing basis.
|